{
    "nctId": "NCT00386087",
    "briefTitle": "Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy",
    "officialTitle": "A Phase II Study of Oral Enzastaurin in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane-Containing Regimen",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 41,
    "primaryOutcomeMeasure": "To determine the effects of enzastaurin in the treatment of patients with breast cancer by measuring its ability to reduce the size of the tumor or prevent further increases in tumor size.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Clinical diagnosis of metastatic breast cancer or recurrent breast cancer where surgery can not be done for curative intent\n* Have received prior therapy with an anthracycline (class of drugs) and a taxane (class of drugs).\n* Tumors must not be positive for HER2, but if positive, the treatment plan should not include further treatment with the drug Herceptin.\n* Disease that can be definitely measured on Cat Scans or other radiological tests.\n* May have received high dose chemotherapy for autologous stem cell support greater than or equal to 6 months of starting this study.\n\nExclusion Criteria:\n\n* More than 2 chemotherapy regimens for metastatic or locally recurrent disease.\n* Have brain cancer from breast cancer\n* Pregnant or breastfeeding\n* Have an inability to swallow tablets\n* Within 6 months have had a serious heart condition",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}